The largest community of pharma leaders

Woebot Health Names Timothy Mariano Vice President and Medical Director

SAN FRANCISCO–(BUSINESS WIRE)–Woebot Health announced today that it has appointed Timothy Mariano, MD, PhD, MSc, as vice president and medical director. In the newly created position, Dr. Mariano will provide medical, clinical and regulatory leadership for the company’s growing pipeline of prescription digital therapeutics that are designed to scale to fill gaps in care and engage people to improve their mental health outcomes. Reporting to Chief Commercial and Strategy Officer Monique Levy, Dr. Mariano will also advance scientific partnerships and be a core member of the company’s Scientific Advisory Board.

“Woebot Health is at the forefront of a new age of engaging and effective digital therapeutics. It’s a very exciting time to be joining such a dynamic company.”

“A practicing psychiatrist with extensive training and experience in engineering, psychology and drug development, Dr. Mariano brings an outstanding combination of skills to Woebot Health at just the right moment,” said Levy. “Developing efficacious digital therapeutics that are truly responsive and related requires working at the frontier of AI, conversational UX, science and regulatory strategy at the same time. We’re poised to make mental health accessible to all, and Dr. Mariano’s addition to the team will help to ensure that we take the fastest, most effective path there,” Levy added.

Before joining Woebot Health, Dr. Mariano was medical director at Sage Therapeutics, where he led the clinical development, medical monitoring and regulatory strategy for several early and late-stage studies, including the SHORELINE Study, a large clinical trial that is following patients with major depressive disorder (MDD) and evaluating the safety and tolerability of the company’s Zuranolone investigational medication. Prior to joining Sage Therapeutics, Dr. Mariano was an assistant psychiatrist at Brigham and Women’s Hospital and an instructor at Harvard Medical School. He was also a consultant to Ad Scientiam, a developer of digital patient monitoring solutions, and to Janssen Pharmaceuticals for its esketamine program for depression. Before starting his consulting work, Dr. Mariano completed his research-track residency training in psychiatry at Brown University’s Warren Alpert Medical School.

“The pandemic era has made it clear that more novel and engaging digital tools are needed to help people access mental health care in their moment of need,” Dr. Mariano said. “Woebot Health is at the forefront of a new age of engaging and effective digital therapeutics. It’s a very exciting time to be joining such a dynamic company.”

A licensed psychiatrist, Dr. Mariano will continue his practice at the Providence VA Medical Center in Rhode Island, his research affiliation at the Center for Neurorestoration and Neurotechnology (CfNN), and his academic position as Adjunct Assistant Professor of Biology and Human Behavior at Brown University.

Dr. Mariano holds a Bachelor of Science degree in biomedical engineering from Harvard College; completed his medical training and a PhD in biomedical engineering at Case Western Reserve University; and holds a Master of Science degree in experimental psychology from the University of Oxford. A prolific researcher with dozens of articles published in peer-reviewed publications, Dr. Mariano’s scholarly interests have focused on noninvasive brain stimulation for neuropsychiatric disorders and, more recently, novel teletherapy approaches utilizing mobile technology to reduce pain-related disability and mood symptoms.

About Woebot Health

Woebot Health’s mission is to make mental health radically accessible. Our breakthrough technology is engineered to engage, bringing the art and science of effective therapy together in a portfolio of targeted digital therapeutics and behavioral health products that scale to fill gaps in care and motivate people to take care of their mental health for a lifetime. Headquartered in San Francisco, Woebot Health is funded in part by venture capital firms New Enterprise Associates (NEA), Jazz Venture Partners L.P., and Social Discovery Ventures, with participation from Andrew Ng’s AI Fund. For more information, please visit or follow Woebot on FacebookTwitter and LinkedIn.


Margot Carlson Delogne
Woebot Health
(781) 492-1039

Source Business Wire Health: Pharmaceutical News Read More

Recent Articles